Skip to main content
✦Prime Rate:7.00%✦Fed Funds:3.88%✦5 Yr Treasury:4.95%↓✦10 Yr Treasury:5.10%↓✦30 Yr Treasury:5.43%↓✦30 Yr Mortgage:7.11%·Updated Nov 12, 2026✦Prime Rate:7.00%✦Fed Funds:3.88%✦5 Yr Treasury:4.95%↓✦10 Yr Treasury:5.10%↓✦30 Yr Treasury:5.43%↓✦30 Yr Mortgage:7.11%·Updated Nov 12, 2026
Rates
Medicap Pharmacy

Medicap Pharmacy

The total investment to open a Medicap Pharmacy franchise ranges from $50,000 to $408,680. The initial franchise fee is $50,000. Ongoing royalties are 3% plus a 0.5% advertising fee.

What is the Medicap Pharmacy franchise?

Medicap Pharmacy offers entry into community pharmacy and other essential healthcare services through a structured franchise model. The brand was founded in 1971 in Des Moines, Iowa, although another source lists 1972, and began as Medicine Chest, a retail concept built around patient care, convenience, and pharmaceutical cost savings. Franchising began in 1973, with another source citing 1974. Medicap Pharmacy operates under Medicine Shoppe International, or MSI, part of Cardinal Health. Medicine Shoppe International, Inc. acquired Medicap Pharmacies Inc. in December 2003, when Medicap franchised 181 community pharmacies across 34 states. The main office is in West Des Moines, Iowa, with corporate facilities in Dublin, Ohio. The franchise database reports 56 total units, 96 franchised units, and 0 company owned units. Other market estimates value global pharmacy at USD 2.4 trillion in 2024, with growth to USD 4.1 trillion by 2035. PeerSense presents independent franchise research for buyers reviewing this opportunity and its financing needs. PeerSense is a commercial capital advisory firm, not a lender.

The pharmacy industry has several reported market size estimates. One places the global market at USD 1.35 trillion in 2024 and USD 2.06 trillion by 2030. Another estimates USD 1.49 trillion in 2025 and USD 1.96 trillion by 2030. A separate estimate lists USD 1,315.2 billion in 2023 and USD 1,914.6 billion by 2032. Another places the market at USD 2.4 trillion in 2024, USD 2.5 trillion in 2025, and USD 4.1 trillion by 2035. Reported compound annual growth rates range from 4.3% for 2023 to 2032 to 7.3% for 2025 to 2030, with 5% projected for 2024 to 2035. Stable healthcare needs, an aging population, and higher prescription volumes support demand. Chronic conditions including cancer, diabetes, and cardiovascular disease affect approximately 133 million Americans and contribute to higher healthcare spending. Pharmacies are investing in analytics and personalization as customer focused models gain ground. Over the counter products are projected to grow at a compound annual growth rate of 7% to 8% from 2025 to 2030, while e pharmacy is projected to grow at 12% to 13% over the same period. Digital prescription systems and value based care are also changing distribution and service delivery.

Reported Medicap Pharmacy investment figures vary by source and business model. The franchise fee is listed as $50,000 in the database, while web research reports $3,000 to $15,000. Another source lists as much as $193,940, so buyers should review the current Franchise Disclosure Document. The database reports total initial investment of $50,000 to $408,680. Other estimates place the average initial investment at $130,000 to $961,000 for a franchised center. A new location is estimated at $478,050 to $961,440, while converting an existing pharmacy is estimated at $130,000 to $582,440. Additional reported ranges are $22,100 to $447,000, $330,050 to $699,414, $330,050 to $690,039, and $130,000 to $894,876. These figures compare with sub sector averages of $294,531 to $623,123 and reflect inventory, equipment, and regulatory requirements. Ongoing fees include a royalty of 3% of gross sales and a marketing and advertising fee of 1% of gross sales. Reported liquidity requirements include about $55,000, another source’s minimum cash range beginning at $65,000, and working capital of $50,000 to $70,000. MSI and its parent, Cardinal Health, provide corporate infrastructure and may affect financing considerations. The overall investment falls within a mid to premium range for franchise buyers.

The operating model combines prescription fulfillment with expanded health services and community relationships. Services include immunizations, point of care testing, one on one consultations, medication packaging, medication synchronization, diabetes care supplies, medical equipment, glucose testing, and cholesterol screening. These services generally require qualified pharmacists and support staff, although specific staffing requirements are not detailed. Medicap Pharmacy provides initial training for new franchisees, while one source reports an initial training program of 0 hours, potentially indicating experienced pharmacist or pre qualification expectations. Item 11 of the Franchise Disclosure Document should provide the program’s length and content. Ongoing support includes a Franchise Business Consultant, along with specialists in marketing, managed care, operations, and finance. The franchisor also assists with compliance, location selection, reimbursement processes, and other needs of independent pharmacy owners. Franchisees can connect with a pharmacist network to share practices and compare performance. Preferred locations generally have aging demographics, limited pharmacy competition, strong healthcare infrastructure, and stable economic indicators. The stated population focus is communities of 10,000 to 50,000, especially areas with limited access to personalized pharmacy services.

Industry figures provide context rather than a unit level forecast. The global pharmacy market is reported at USD 1.35 trillion in 2024 with a projection of USD 2.06 trillion by 2030, and elsewhere at USD 2.4 trillion in 2024 with growth to USD 4.1 trillion by 2035. Forecast compound annual growth rates range from 4.3% to 7.3%. Medicap grew from 28 Iowa pharmacies in 1981 to its 100th location in 1993 and currently reports 96 franchised units and 56 total units in the database. As of 2020 Franchise Disclosure Document data, the brand operated in 24 states, including 41 Midwest locations. MSI and Cardinal Health provide corporate resources that may support unit operations and market positioning. Services such as immunizations, point of care testing, and specialized consultations may create additional revenue sources. Buyers must assess the reported investment of $50,000 to $408,680 in franchise data, or $130,000 to $961,000 in web research, against demand associated with chronic disease and an aging population.

Medicap Pharmacy expanded to 28 Iowa pharmacies by 1981 and opened its first Minnesota location in 1984. The 100th pharmacy opened in 1993. Current sources report 56 total units and 96 franchised units in the franchise database, approximately 54 locations, 67 United States franchises, and 77 United States franchised locations in the 2020 Franchise Disclosure Document. One source reports 237 units in operation. MSI and Medicap stores together represent more than 800 United States locations and over 400 locations in five other countries. The December 2003 acquisition brought Medicap’s 181 community pharmacies in 34 states into Medicine Shoppe International and the Cardinal Health organization. The brand’s differentiation rests on recognition, supply chain and technology resources associated with Cardinal Health, and an emphasis on personalized care and convenience. Medicap is expanding beyond prescription filling through immunizations, point of care testing, and one on one consultations. E pharmacy is projected to grow at a compound annual growth rate of 12% to 13% from 2025 to 2030. The 41 Midwest locations across 24 states in 2020 Franchise Disclosure Document data provide an operating example for additional underserved markets.

A suitable franchise candidate will generally have pharmacy or related healthcare experience, required licenses, and knowledge of pharmaceutical operations and patient care. Specific experience requirements are not stated, but prior management experience in healthcare may help with daily operations and team leadership. Community health and patient focused service are central to the model. Target markets include communities of 10,000 to 50,000 residents with aging demographics, limited pharmacy competition, strong healthcare infrastructure, and stable economic indicators. Potential expansion areas include underserved markets in the Northeast and Southeast, building on the Midwest operating model. The timeline from signing to opening is not provided. The franchisor’s support includes location assistance and reimbursement management. The franchise agreement term is also unspecified and should be reviewed during due diligence.

A Medicap Pharmacy investment provides access to a pharmaceutical market projected to reach USD 4.1 trillion by 2035. Demand is supported by healthcare needs, aging demographics, and chronic diseases affecting approximately 133 million Americans. Reported unit counts vary, including 56 total units, 96 franchised units, and 77 franchised units in the 2020 Franchise Disclosure Document. The brand dates to 1971 and operates within the Cardinal Health organization. Its focus on communities of 10,000 to 50,000 residents and services beyond prescriptions may support expansion in underserved areas. Reported investment ranges include $50,000 to $408,680. PeerSense provides independent due diligence resources, including SBA lending history, a Loan Activity Score of 54, rated Moderate, location maps with Google ratings, Franchise Disclosure Document financial data, and comparison tools. Buyers can review the complete Medicap Pharmacy franchise profile on PeerSense.

Loan Activity Score

58/100

SBA Default Rate

3.8%

Active Lenders

61

According to its Franchise Disclosure Document or public business records, Medicap Pharmacy has 96 locations, all owned by franchisees. Public SBA loan records show 61 lenders made 131 loans to franchisees of Medicap Pharmacy. PeerSense calculates Medicap Pharmacy's score as 58 out of 100, using public SBA loan performance and recent lending activity. Cost figures are based on the 2023 Franchise Disclosure Document. To correct a figure, email the current FDD and the differing item numbers to info@peersense.com, and this page will be updated.

Franchising since 2025 · 96 locations

Investment

$50,000 to $408,680

Franchise Fee

$50,000

Total Units

96

96 franchised

Loan Activity Score
High
58
SBA Lending
22
Lender Quality
9
Transparency
14
Reach
10
Momentum
3

Proprietary PeerSense metric

Moderate
Capital Sources
61SBA lenders

Distinct lenders in public SBA records for Medicap Pharmacy

131

Total SBA loans

$223K

Average loan size

Source: public SBA 7(a) and 504 loan records through December 31, 2025

Referral fee at closing

SBA Lending Activity for Medicap Pharmacy

Loan Activity Score Breakdown

Major Brand (100+ loans)

High Confidence
58out of 100
Moderate
Market Momentum3/35

Are lenders increasingly or decreasingly funding this brand? Growing trends score highest.

Loan Safety22/25

Blended default rate (recent + all time) compared to NAICS sector peers.

Lender Confidence9/15

Quality lenders actively backing this brand, with penalty for lender pullback.

Transparency14/15

FDD availability, Item 19 disclosure, and overall data completeness.

Footprint10/10

Geographic spread of SBA funded locations across states.

SBA Lending Performance

SBA Default Rate

3.8%

vs 9.4% peer avg

SBA Loans

131

Total Volume

$29.2M

Active Lenders

61

7 selective

States

31

vs. SBA Sector Average

+5.6%lower default rate

SBA loan default rate vs. all franchises in the same NAICS sector, not limited to direct competitors

Key Highlights

Low SBA default rate (3.8%)
Item 19 financial data disclosed

Data Insights

Key performance metrics for Medicap Pharmacy based on SBA lending data

SBA Default Rate

3.8%

5.6% below peer avg

SBA Loan Volume

131 loans

Across 61 lenders

Lender Diversity

61 lenders

Avg 2.1 loans per lender

Investment Tier

Mid range investment

$50,000 to $408,680 total

Medicap Pharmacy: Deep SBA Data

Brand specific metrics derived directly from SBA 7(a) approval records: peak lending year, leading state, average loan size, and lender concentration. PeerSense computes these per brand so capital advisors and prospective franchisees can benchmark this opportunity against the rest of the franchise universe.

Peak SBA Year

2003

13 approvals. The best year on record for Medicap Pharmacy.

Top SBA State

Iowa

21 SBA financed Medicap Pharmacy locations, the densest operator footprint.

Average Loan Size

$223K

Median $150K. Use as a sizing anchor when modeling your own Medicap Pharmacy unit.

Lender Concentration

32.1%

Moderately Spread

Share of Medicap Pharmacy approvals captured by the top 3 SBA lenders.

Medicap Pharmacy's SBA lending pipeline peaked in 2003 (13 approvals). The last five fiscal years account for 1% of cumulative volume ($673K approved). Operator density is highest in Iowa with 21 SBA financed locations. Average funded ticket sits at $223K, with the median at $150K. Lender mix is moderately spread: the top three SBA lenders account for 32.1% of approvals. Meaningful choice exists, but specific lenders carry the brand.

Payment Estimator

Loan Amount$40K
Interest Rate9.5%
Term (Years)10 yr

Estimated Monthly Payment

$518

Principal & Interest only

Indicative only, as of November 1, 2026. Not a quote, commitment or offer of credit. Final pricing, leverage and terms are determined by the lender at underwriting, after full transaction materials are reviewed. PeerSense sources the file. The lender sets pricing. What these terms mean.

Locations

Medicap Pharmacy, unit breakdown

Total Units
N/A
Franchisee Owned
n/a
System Owned
n/a
Closed
n/a

Explore Funding for Medicap Pharmacy

Our business financing consultants help connect you with the right lending partners. Referral fee paid at closing.

Optional: checking the consent box lets us call or text you about your funding. You can still submit without it.

Referral fee at closing

Or get an instant analysis

Scan Your Deal Instantly

3 FDDs Available for Medicap Pharmacy

Review franchise fees, investment ranges, royalties, Item 19 financial data, and year over year trends. Request complimentary access through your PeerSense funding advisor.

Medicap Pharmacy

Page Review

Reviewed by Edward L. Freeman, Founder and Managing Director, PeerSense

  • PeerSense is a capital advisory firm that places commercial financing with direct capital sources; the capital source sets final terms.
  • Edward L. Freeman founded PeerSense in January 2020.
  • He is a Registered Franchise Consultant with Business Alliance, Inc., a credential issued in March 2022, and worked as a franchise consultant there from March 2022 to May 2023.
  • His recorded experience includes a $22 million SBA construction loan, with about $16 million funded on the deal.
  • In the 12 months through September 30, 2026, PeerSense tracked 912 publicly announced financings with a disclosed size of $361.32 billion. PeerSense Capital Data Report · Methodology page

Last reviewed LinkedIn profileAbout Edward Freeman

This is not a franchise offering and does not constitute financial, investment, or legal advice. Data is sourced from Franchise Disclosure Documents (FDDs), public filings, and third party sources and may contain inaccuracies. The figures reflect the FDD on file for the year shown and may have been superseded or extracted with errors. PeerSense is not a financial advisor, attorney, or accountant. Always consult the brand's current FDD and seek professional guidance from a qualified attorney, accountant, or financial advisor before making any franchise investment decision. See full Terms & Conditions.